Canada - English - Health Canada

sanis health inc - irbesartan - tablet - 300mg - irbesartan 300mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

sivem pharmaceuticals ulc - irbesartan - tablet - 300mg - irbesartan 300mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

sivem pharmaceuticals ulc - irbesartan; hydrochlorothiazide - tablet - 300mg; 12.5mg - irbesartan 300mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

sivem pharmaceuticals ulc - irbesartan; hydrochlorothiazide - tablet - 300mg; 25mg - irbesartan 300mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

ranbaxy pharmaceuticals canada inc. - irbesartan - tablet - 300mg - irbesartan 300mg - angiotensin ii receptor antagonists

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 300 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental like

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: iron oxide red; iron oxide yellow; croscarmellose sodium; silicon dioxide; carnauba wax; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 3350; iron oxide black - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: silicon dioxide; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; magnesium stearate; carnauba wax; croscarmellose sodium; iron oxide red; titanium dioxide; hypromellose; macrogol 3350; iron oxide black - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - irbesartan; hydrochlorothiazide - tablet - 300mg ; 12.5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - irbesartan - tablet - 75 milligram(s) - angiotensin ii antagonists, plain; irbesartan